Published in Proc R Soc Med on January 01, 1908
The Intermittent Infectiousness of Scarlet Fever. Proc R Soc Med (1909) 0.75
Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). Br J Pharmacol (1971) 6.11
Pharmacokinetics of inhaled substances. Postgrad Med J (1975) 3.52
Isoprenaline resistance and the use of pressurised aerosols in asthma. Lancet (1968) 3.33
Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther (1976) 3.13
Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol (1976) 2.78
Blood concentrations in man of fluorinated hydrocarbons after inhalation of pressurised aerosols. Lancet (1970) 2.48
The fate of isoprenaline administered by pressurized aerosols. Br J Pharmacol (1970) 2.43
Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. Br J Clin Pharmacol (1978) 2.14
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
The metabolic fate of DL(7-3H)isoprenaline in man and dog. Biochem J (1969) 2.06
Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet (1977) 2.01
Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther (1977) 1.91
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol (1981) 1.81
Mixed function oxidase activity in microsomal fractions of human liver biopsy specimens [proceedings]. Br J Clin Pharmacol (1978) 1.75
Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol (1980) 1.69
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
The fate of ethyltin and diethyltin derivatives in the rat. Biochem J (1967) 1.62
CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res (1994) 1.49
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol (1981) 1.47
The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol (1980) 1.40
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol (1990) 1.38
Metabolism of isoprenaline in dog and man. Br J Pharmacol (1972) 1.38
Metabolism of isoprenaline after aerosol and direct intrabronchial administration in man and dog. Br J Pharmacol (1974) 1.32
Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol (1981) 1.32
Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol (1983) 1.29
A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol (1988) 1.28
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol (1986) 1.25
Fluorescence studies on some hydroxypyridines including compounds of the vitamin B6 group. Biochem J (1966) 1.23
Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci (1971) 1.20
Nucleosomes bind to cell surface proteoglycans. J Biol Chem (1999) 1.20
Pharmacokinetics of metoclopramide. Lancet (1979) 1.20
The fate of inhaled terbutaline. Eur J Respir Dis Suppl (1984) 1.20
Species and sex differences in electron transport systems in liver microsomes and their relationship to ethylmorphine demethylation. Life Sci (1969) 1.20
Concentration effect studies with oral metoclopramide. Br J Clin Pharmacol (1979) 1.18
Mechanisms of cell death. Arch Toxicol (1991) 1.17
Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med (1977) 1.17
Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol (1977) 1.16
Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro. Eur J Clin Pharmacol (1981) 1.12
Metabolism of isoprenaline in the intestine. J Pharm Pharmacol (1974) 1.12
Disposition and oxidative metabolism of phenylbutazone in man. Eur J Clin Pharmacol (1977) 1.09
The conduct of initial drug studies in man. Br Med Bull (1970) 1.08
Sex differences in the kinetic constants for the N-demethylation of ethylmorphine by rat liver microsomes. Biochem Pharmacol (1968) 1.07
The analysis of terbutaline in biological fluids by gas chromatography electron impace mass spectrometry. Biomed Mass Spectrom (1979) 1.03
Differences in the metabolism of drugs depending upon their routes of administration. Ann N Y Acad Sci (1971) 1.03
"First-pass" metabolism of paracetamol in rat liver. J Pharm Pharmacol (1974) 1.02
Antipyrine as an in vitro probe of mixed function oxidase activity [proceeding]. Br J Clin Pharmacol (1980) 1.02
Detection and measurement of MeIQx in human urine after ingestion of a cooked meat meal. Carcinogenesis (1989) 1.02
Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.01
Kinetics of paraquat elimination in the dog. Toxicol Appl Pharmacol (1981) 1.00
The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol (1989) 1.00
Letter: Clonidine overdose. Br Med J (1975) 0.99
Heterocyclic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol (1996) 0.98
Extra-nuclear location of histones in activated human peripheral blood lymphocytes and cultured T-cells. Biochem Pharmacol (1995) 0.98
Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol (1990) 0.97
Mechanisms of cell death. Trends Pharmacol Sci (1989) 0.96
The metabolism of clonidine and related imidazoline derivatives in rat liver [proceedings]. Br J Pharmacol (1978) 0.96
Human cytochromes P-450. Xenobiotica (1984) 0.96
N-acetylcysteine for paracetamol overdose. Lancet (1986) 0.96
Apparent resistance to hypotensive effect of clonidine. Br Med J (1977) 0.96
Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c. Biochem Pharmacol (1986) 0.95
The metabolism of sympathomimetic bronchodilator drugs by the isolated perfused dog lung. Xenobiotica (1973) 0.95
Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br J Clin Pharmacol (1985) 0.95
Competition for sulphate during detoxification in the gut wall. Nature (1975) 0.94
Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res Hum Retroviruses (1997) 0.94
Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) by human liver microsomes. Carcinogenesis (1994) 0.93
Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Biochem Pharmacol (1985) 0.92
Reduction of circulating 25-hydroxyvitamin D by antipyrine. Br J Clin Pharmacol (1979) 0.92
The influence of the route of administration on urinary metabolites of isoetharine. Xenobiotica (1974) 0.92
Reversal of acetaminophen toxicity in isolated hamster hepatocytes by dithiothreitol. Toxicol Appl Pharmacol (1986) 0.92
Interindividual variation in kinetics of infused epinephrine. Clin Pharmacol Ther (1979) 0.92
The measurement of MeIQx adducts with mouse haemoglobin in vitro and in vivo: implications for human dosimetry. Carcinogenesis (1991) 0.91
Pharmacokinetic and concentration-effect studies with metoclopramide [proceedings]. Br J Clin Pharmacol (1977) 0.91
Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol (1994) 0.91
Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol (1982) 0.91
Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by N-acetyl-L- but not N-acetyl-D-cysteine. Br J Pharmacol (1990) 0.91
Identification and location of alpha-helices in mammalian cytochromes P450. Biochemistry (1989) 0.91
Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis. Br J Clin Pharmacol (1976) 0.90
Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol (1998) 0.90
Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis (1994) 0.89
Freshly isolated hepatocytes as a model for studying the toxicity of paracetamol. Food Chem Toxicol (1987) 0.88
Attempts to phenotype human liver samples in vitro for debrisoquine 4-hydroxylase activity. Br J Clin Pharmacol (1985) 0.88
Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Biochem Pharmacol (1999) 0.88
Biphasic Michaelis-Menten kinetics for ethoxycoumarin and phenacetin metabolism by human and rat hepatic monooxygenases [proceedings]. Br J Pharmacol (1979) 0.88
Food-derived heterocyclic amine mutagens: variable metabolism and significance to humans. Drug Metab Dispos (2001) 0.87
Bis(trifluoromethyl)aryl derivatives for drug analysis by gas chromatography electron capture negative ion chemical ionization mass spectrometry. Application to the measurement of low levels of clonidine in plasma. Biomed Mass Spectrom (1984) 0.87
Inter-relatedness of some isoenzymes of cytochrome P-450 from rat, rabbit and human, determined with monoclonal antibodies. Biochem J (1986) 0.87
Cytochrome P-450 and drug oxidation. Biochem J (1969) 0.87
Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. Carcinogenesis (1985) 0.87
In vivo absorption studies with paraquat and diquat in the dog [proceedings]. Br J Pharmacol (1976) 0.87
Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat. Biochem Pharmacol (1989) 0.87
Inhibition of cytochrome P-450-dependent oxidation reactions by MAO inhibitors in rat liver microsomes. Biochem Pharmacol (1987) 0.86
Centrally acting drugs in antihypertensive therapy. Br J Clin Pharmacol (1980) 0.86
Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis (1993) 0.86
Determination of the N-acetyl metabolites of 4,4'-methylene dianiline and 4,4'-methylene-bis(2-chloroaniline) in urine. Biomed Environ Mass Spectrom (1988) 0.86
Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite. Biochem Pharmacol (1987) 0.84
Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine(PhIP) at the Chinese hamsters hprt locus. Carcinogenesis (1996) 0.84